Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration‐Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration‐Resistant Prostate Cancer

Published:2022-04-12 Issue:6 Volume:111 Page:1296-1306
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Qin Sisi¹,Gao Huanyao¹,Kim Wootae¹²,Zhang Huan¹,Gu Yayun¹,Kalari Krishna R.³,Sinnwell Jason P.³,Scholz Jodi A.⁴,Xie Fang¹,Yin Ping¹²,Yu Jia¹,Qin Bo¹,Zhuang Yongxian¹,Wei Lixuan¹,Tan Winston⁵,Bryce Alan H.⁶,Weinshilboum Richard M.¹,Wang Liewei¹

Affiliation:

1. Department of Molecular Pharmacology and Experimental Therapeutics Mayo Clinic Rochester Minnesota USA

2. Department of Oncology Mayo Clinic Rochester Minnesota USA

3. Department of Health Sciences Research Mayo Clinic Rochester Minnesota USA

4. Department of Comparative Medicine Mayo Clinic Rochester Minnesota USA

5. Division of Hematology/Oncology Department of Internal Medicine Mayo Clinic Jacksonville Florida USA

6. Division of Hematology/Oncology Department of Internal Medicine Mayo Clinic Phoenix Arizona USA

Funder

National Institutes of Health

U.S. Department of Defense

Publisher

Wiley